NO992186L - System med forsinket avlevering for syresensitive medikamenter - Google Patents

System med forsinket avlevering for syresensitive medikamenter

Info

Publication number
NO992186L
NO992186L NO992186A NO992186A NO992186L NO 992186 L NO992186 L NO 992186L NO 992186 A NO992186 A NO 992186A NO 992186 A NO992186 A NO 992186A NO 992186 L NO992186 L NO 992186L
Authority
NO
Norway
Prior art keywords
delivery system
acid
barrier
omeprazole
pulsatile
Prior art date
Application number
NO992186A
Other languages
English (en)
Norwegian (no)
Other versions
NO992186D0 (no
Inventor
Vinay K Sharma
Original Assignee
Sharmatek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sharmatek Inc filed Critical Sharmatek Inc
Publication of NO992186L publication Critical patent/NO992186L/no
Publication of NO992186D0 publication Critical patent/NO992186D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
NO992186A 1996-11-06 1999-05-05 System med forsinket avlevering for syresensitive medikamenter NO992186D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74098196A 1996-11-06 1996-11-06
PCT/US1997/020851 WO1998019668A1 (en) 1996-11-06 1997-11-05 Delayed delivery system for acid-sensitive drugs

Publications (2)

Publication Number Publication Date
NO992186L true NO992186L (no) 1999-05-05
NO992186D0 NO992186D0 (no) 1999-05-05

Family

ID=24978866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992186A NO992186D0 (no) 1996-11-06 1999-05-05 System med forsinket avlevering for syresensitive medikamenter

Country Status (7)

Country Link
EP (1) EP0941074B1 (de)
AT (1) ATE271379T1 (de)
AU (1) AU5179898A (de)
DE (1) DE69729950T2 (de)
NO (1) NO992186D0 (de)
WO (1) WO1998019668A1 (de)
ZA (1) ZA979937B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ATE297194T1 (de) * 1999-12-16 2005-06-15 Medinfar Produtos Farmaceutico Neue stabile mehreinheitliche substituierte benzimidazole enthaltende pharmazeutische präparate
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ES2663873T3 (es) * 2001-10-29 2018-04-17 Massachusetts Institute Of Technology Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
WO2004080439A1 (ja) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 高濃度に活性成分を球形核に付着させた医薬組成物
WO2005051362A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
EP1755566A2 (de) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stabile pharmazeutische formulierungen von benzimidazolverbindungen
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20090104264A1 (en) * 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
EP1967183A4 (de) * 2005-12-28 2011-02-23 Takeda Pharmaceutical Feststoffpräparat mit kontrollierter freisetzung
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN104721168A (zh) * 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I

Also Published As

Publication number Publication date
DE69729950D1 (de) 2004-08-26
ZA979937B (en) 1999-05-18
EP0941074B1 (de) 2004-07-21
EP0941074A1 (de) 1999-09-15
ATE271379T1 (de) 2004-08-15
WO1998019668A1 (en) 1998-05-14
NO992186D0 (no) 1999-05-05
AU5179898A (en) 1998-05-29
DE69729950T2 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
NO992186D0 (no) System med forsinket avlevering for syresensitive medikamenter
KR101078636B1 (ko) 약학 활성원의 지연 및 조절된 방출을 위한 생약 미세입자구강 제제
AU1488295A (en) Pharmaceutical composition
DE60021604D1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
NO982302L (no) Farmas°ytisk sammensetning
PT1117386E (pt) Administracao enterica e colonica utilizando capsulas de hpmc
NZ237516A (en) Device for drug delivery to intestinal tract comprising a core of active ingredient together with osmotically activated expulsion agent and an outer coating containing a hydrophobic material to assist in delaying release
MX9500885A (es) Preparacion farmaceutica para administracion oral.
NO20003640L (no) Ny doseringsform
RU99126869A (ru) Фармацевтический препарат омепразола
IT1246382B (it) Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
NZ711298A (en) Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
DK0754452T3 (da) Farmaceutisk præparat i form af en overtrukket kapsel, der frigives i den nedre del af fordøjelsessystemet
US5824341A (en) Composition providing selective release of an active ingredient
MXPA05001243A (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion.
WO2001024777A1 (en) Coated solid dosage forms
KR20220113697A (ko) 알칼리제 및 장용성 코팅층을 포함하는 투여 형태
AU736357B2 (en) Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient
WO2001078681A1 (fr) Systeme d'administration de medicament empechant l'interaction pharmacocinetique entre les medicaments et procede correspondant
AU2009247712B2 (en) Compositions and methods for inhibiting gastric acid secretion
US20060043207A1 (en) Apparatus, kit and related methods for administering substances
US6074669A (en) Controlled drug delivery system for diltiazem
AU2014239683A1 (en) Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
EP4013401A1 (de) Gegenstände und verfahren zur verabreichung therapeutischer mittel
JPH06256166A (ja) 薬物放出制御製剤

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application